Drug intelligence / Profile preview

ibuprofen + paracetamol + codeine

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

A combination analgesic containing ibuprofen (a non-steroidal anti-inflammatory drug), paracetamol (acetaminophen, a non-opioid analgesic), and codeine (an opioid analgesic). This triple combination would be used for moderate to severe pain relief. Each component works through different mechanisms: ibuprofen inhibits prostaglandin synthesis, paracetamol acts centrally, and codeine affects pain receptors in the central nervous system.

Other names: ibuprofen + paracetamol + codeine phosphateibuprofen + acetaminophen + codeineibuprofen 400 mg + paracetamol 1000 mg + codeine 60 mg

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ibuprofen + paracetamol + codeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + paracetamol + codeine.